Reports Q4 revenue $27.4M, consensus $26.24M. "The year is off to an excellent start with a strong Revio order book and continued customer enthusiasm for the new product," said Christian Henry, President, and CEO. "Momentum is clearly building for highly accurate, long-read solutions, with Nature Methods naming long-read sequencing its ‘Method of the Year’ and studies like the preprint from All of Us researchers concluding that we should continue developing population-scale cohorts sequenced with long-reads only."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PACB:
- PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
- Pac Bio options imply 4.4% move in share price post-earnings
- Pacific Biosciences initiated with a Neutral at UBS
- Pacific Biosciences 17.5M share Spot Secondary priced at $10.00
- Pacific Biosciences $150M Spot Secondary; price range $10.00-$10.25